Who Paid My Doc
Jacob Vanhouten
Public Health & General Preventive Medicine Tucson, AZ Medical Doctor
NPI 1821595083 CMS profile 8807616
2940 S 6Th Ave, Tucson, AZ 85713
General payments
$135
Research payments
$0
Ownership & investment interest
$0
Through program year 2024, Jacob Vanhouten of Tucson, AZ is reported in the CMS Open Payments database as having received $135 across 2 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 55th percentile of Public Health & General Preventive Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $17 | 1 | |
| 2020 | General | $118 | 1 |
Beside peers
- Jacob Vanhouten
- Public Health & General Preventive Medicine median
- Middle half of Public Health & General Preventive Medicine
- National median
In program year 2025, general payments to Jacob Vanhouten were reported at $0. Among 185 Public Health & General Preventive Medicine profiles paid that year, the median was $99 and the middle half received between $32 and $365.
Show as a table
| Year | Jacob Vanhouten | Public Health & General Preventive Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $99 | $22–$287 | $163 |
| 2020 | $118 | $101 | $21–$478 | $114 |
| 2021 | $0 | $99 | $31–$856 | $132 |
| 2022 | $0 | $79 | $24–$340 | $149 |
| 2023 | $0 | $102 | $28–$326 | $160 |
| 2024 | $17 | $98 | $27–$291 | $164 |
| 2025 | $0 | $99 | $32–$365 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 43 drugsPart D claims
1,554
Drug cost
$50,249
Branded share of claims
9.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ozempic Semaglutide | Brand | 13 | $15,759 | |
| Jardiance Empagliflozin | Brand | 17 | $15,410 | |
| Humalog Kwikpen U-100 Insulin Lispro | Brand | 16 | $1,869 | |
| Omeprazole | Generic | 78 | $1,544 | |
| Atorvastatin Calcium | Generic | 163 | $1,375 | |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | Brand | 12 | $1,348 | |
| Ibuprofen | Generic | 33 | $1,051 | |
| Losartan Potassium | Generic | 94 | $1,051 | |
| Lisinopril | Generic | 129 | $823 | |
| Amlodipine Besylate | Generic | 116 | $725 |
The 10 drugs with the highest cost, of 43 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 7 billing codesPaid by Medicare
$2,129
Medicare patients
31
Services billed
34
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 61% | |
| Arthritis | 35% | |
| Alzheimer's or dementia | 0% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
2 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Public Health & General Preventive Medicine in Arizona
Practitioners in the same specialty and state, ranked by reported value.
All Public Health & General Preventive Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Arizona
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.